AI assistant
Silence Therapeutics plc — Director's Dealing 2025
Jan 2, 2025
33536_dirs_2025-01-02_cd87cc87-8779-4203-b79a-f3c23125d390.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Silence Therapeutics plc (SLN)
CIK: 0001479615
Period of Report: 2025-01-02
Reporting Person: Davidson Michael H. (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 12993 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Share Option (Right to Buy) | $7.87 | 2032-01-06 | Ordinary Shares (48000) | Direct | |
| Share Option (Right to Buy) | $5.13 | 2033-09-14 | Ordinary Shares (48000) | Direct | |
| Share Option (Right to Buy) | $5.90 | 2034-01-04 | Ordinary Shares (48000) | Direct |
Footnotes
F1: This option vested or shall vest in equal monthly installments over a three-year period measured from one month following January 6, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
F2: This option vested or shall vest in equal monthly installments over a three-year period measured from one month following September 14, 2023, subject to the Reporting Person's continuous service as of the applicable vesting date.
F3: This option vested or shall vest in equal monthly installments over a three-year period measured from one month following January 4, 2024, subject to the Reporting Person's continuous service as of the applicable vesting date.